Our Core is Research & Development (R&D)

As a science-based organisation, R&D activities are one of the most important contributions to our commitment to restoring brain health. We dedicate R&D efforts based on both internal and external innovation, to develop new and advanced medicines within a number of indications for the treatment of brain diseases.

Lundbeck’s R&D is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases. This requires comprehensive research into the biology and disease mechanism, as well as improved understanding of research targets and clinical outcomes. Over the years, we have built a broad and robust platform within psychiatry and neuro-degeneration, which allows us to use small molecules, antibodies and vaccines in the development of new medicines that can treat symptoms more effectively and potentially also alter the course of the diseases.

Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the brain disease area and new technologies. We work in state-of-the-art laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.

We work together as individuals towards common goals. We seek to constantly develop and improve our scientific and personal skills and qualifications. This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organisation. Publication of our scientific results is a natural part of our participation as active members in the international scientific community.

Lundbeck’s long experience and continuous work within diseases of the brain has provided us with a strong global network in preclinical and clinical neuroscience research. It is essential for us to maintain our strong internal R&D capabilities and to build external alliances to supplement our internal capabilities, taking advantage of the increased opportunities provided by innovative technologies.

Our R&D strategy provides a future platform from which Lundbeck can discover and develop treatments with clearly documented effects on biologically defined patient groups. This is based on our digital approach to optimise the treatment of brain diseases. It is expected that society’s demand for these new types of treatments will increase.

Recently, however, a large-scale analysis of post-mortem brains revealed distinctive molecular traces in people with psychiatric disorders. An international team of researchers has reported that five major psychiatric disorders have patterns of gene activity that often overlap but also vary in disease-specific - and sometimes counterintuitive - ways. The findings might someday lead to diagnostic tests and novel therapies.¹